• About CLENPIQ
  • Improved Insurance
    Coverage
  • Simple Prep
A right start for a clean finish

See how a next-generation low-volume,
ready-to-drink bowel prep
can help support a
successful colon cleanse for your patients1

Learn More

Now CLENPIQ has greater access with exclusivity
for 3 of 4 CVS Health and Aetna Formularies*

Covered through UHC/AARP and SilverScript for most
Medicare patients.

SEE SAVINGS

*CLENPIQ is the exclusive, preferred branded bowel prep on the
Standard, Advanced Control, and Value Formularies through CVS
Health and Aetna.

INSTRUCTIONS FOR USE

See our resources for completing the CLENPIQ prep,
including a dosage tool.

HELP PATIENTS PREP
Learn how to get the most from your
CLENPIQ experience. GET IN TOUCH

Split-dose CLENPIQ demonstrated proven efficacy in
cleansing the entire colon1,2*

88% of patients achieved successful cleansing of the overall colon1,2*

Overall Color Chart

The primary endpoint was the proportion of patients with successful colon cleansing, defined as “excellent” or “good”

Scoring was performed before washing and suctioning

*Trial Design: The safety and efficacy of CLENPIQ were evaluated in a randomized, multicenter, controlled, assessor-blinded trial. CLENPIQ® (sodium picosulfate, magnesium oxide, and anhydrous citric acid) Oral Solution (SPMC) was administered in a split-dose regimen against an oral powder (for reconstitution) (P/MC powder) and efficacy was evaluated using 2 different measurement scales.2 In this trial, CLENPIQ patients were instructed to drink at least five 8-ounce glasses of clear liquid within 5 hours of the first dose of CLENPIQ and at least four 8-ounce glasses of clear liquid within 4 hours of the second dose.2

Split-dose CLENPIQ demonstrated proven efficacy in cleansing all segments of the colon2*

94% of patients achieved successful cleansing of the ascending colon2*

Segmental colon

Assessed using the Boston Bowel Preparation scale2
Asending Colon Chart
Transverse Colon Chart
Decending Colon Chart

Secondary efficacy endpoints were the proportion of patients with successful cleansing of the ascending, transverse, and descending colon, defined as a segmental score of “3” or “2”2

Scoring was performed after washing and suctioning2

Established safety profile1,2

The most common adverse reactions (≥ 2%) observed in the adult CLENPIQ split-dose clinical trial were nausea (3%), headache (3%), hypermagnesemia (2%), abdominal pain (2%), and dehydration or dizziness (2%).1,2

Hypermagnesemia levels were transient and not associated with any clinical significant sequelae. Eight of the 9 patients with hypermagnesemia returned to baseline within 24 to 48 hours. One patient returned to baseline by the day 7 follow-up visit.1,2

1% of patients taking CLENPIQ experienced vomiting.2


Patient compliance and tolerability were evaluated2†

Results from the Mayo Clinic Bowel Preparation Tolerability Questionnaire:

  • 99% of patients completed the majority of the CLENPIQ prep
  • 98% said they would be mostly or somewhat willing to take CLENPIQ again2
  • 90% felt that the tolerability of CLENPIQ was “easy” or “acceptable”2

Trial Design: The efficacy and safety of CLENPIQ were evaluated in a randomized, multicenter, controlled, assessor-blinded trial. CLENPIQ® (sodium picosulfate, magnesium oxide, and anhydrous citric acid) Oral Solution (SPMC) was administered in a split-dose regimen against an oral powder (for reconstitution) (P/MC powder) and efficacy was evaluated using 2 different measurement scales.2

Subject compliance and tolerability with the bowel preparations were assessed by the validated Mayo Clinic Bowel Prep Tolerability Questionnaire, administered to patients on the day of their colonoscopies prior to the procedure.2

§Majority was defined as <25% of the bowel prep remaining after dosing.

Results from the questionnaire demonstrated that there was a high degree of tolerability and willingness to use CLENPIQ in the future2

Can CLENPIQ help your patients prep for a successful procedure?

CLENPIQ is the next-generation low-volume, ready-to-drink bowel prep1

LOWEST VOLUME OF ACTIVE MEDICATION COMPARED WITH SUPREP®, PLENVU®, AND MoviPrep®1,4-6*
NO MIXING OR DILUTING1
SUPPLIED IN TWO 5.4-OZ, READY-TO-DRINK BOTTLES1*

*Additional clear liquids are required for hydration.1,4-6

CLENPIQ provides split-dose Instructions for Use that are easy to follow

CLENPIQ provides split-dose Instructions for Use that are easy to follow

Click here to download the full instructions.

To open the CLENPIQ bottle: Place the bottle on a flat surface. Push down on the cap while twisting to the left (counterclockwise). Twist the cap until you see the white plastic ring under the cap is broken.

Clenpiq Bottle Opening

Drink, hydrate, repeat1

Clenpiq Split-Dose
Night Before
5:00 to 9:00 PM
Clenpiq Bottle and 5 Glasses of Water

Drink 1 bottle of CLENPIQ
and five 8 ounce (oz) cups (40 oz)
or more of clear liquids.
Finish liquids over the next 5 hours.

MORNING OF
5 hours before the procedure
Clenpiq Bottle and 4 Glasses of Water

Drink the other bottle of CLENPIQ and four 8 ounce (oz) cups (32 oz) or more of clear liquids. Finish liquids 2 hours before your colonoscopy or as advised by your doctor.

See below for step-by-step instructions.

Patient should hydrate on the day before the procedure and consume only clear liquids.1,3

CLENPIQ Dosing Assistant

Recommend this tool to your patients so they can make their own CLENPIQ dosing schedule.

Please follow the instructions from your doctor for taking CLENPIQ.

1 Day of Colonoscopy

Month:
Day:
Year:

Please enter valid date

2 Time of Colonoscopy

Choose the schedule decided by you and your doctor. If you have any questions, please call your doctor’s office.

Two-day Split-dosing
Time of Appointment:

3 Recommended
Time to Start

Time and day of colonoscopy:

--:-- -- on --/--/----

Dose 1:

--:-- -- on --/--/----

Dose 2:

--:-- -- on --/--/----

Stop drinking liquids at:

--:-- -- on --/--/----

Icon of Clepiq Logo on Papers

Download easy-to-follow instructions for your patients taking split-dose CLENPIQ.

Step-By-Step Split-Dose Administration1

Dose 1 – On the day before the colonoscopy1:

  • Instruct patients to consume only clear liquids (no solid food or dairy) on the day before the colonoscopy up until 2 hours before the time of the colonoscopy
  • Take the first dose (1 bottle) of CLENPIQ during the evening before the colonoscopy (eg, 5:00 to 9:00 PM)
  • Follow CLENPIQ by drinking at least five 8-ounce cups (cup provided) of clear liquids (40 ounces total) within 5 hours and before bed
  • If severe bloating, distention, or abdominal pain occurs following the first dose, delay the second dose until the symptoms resolve

Dose 2 – Next morning on the day of the colonoscopy (start approximately 5 hours prior to colonoscopy)1:

  • Continue to consume only clear liquids (no solid food or dairy)
  • Take the second dose (the second bottle) of CLENPIQ
  • Following the CLENPIQ dose, drink at least three 8-ounce cups (cup provided) of clear liquids (24 ounces) at least 2 hours before the colonoscopy

Hydration is an important part of the prep

Patients can hydrate with any of the following clear liquids:

  • Water (plain or flavored)
  • Black coffee or tea (no milk, cream, soy, or nondairy creamer)
  • Clear broth or bouillon
  • Sports drinks (not red or purple)
  • Clear juices without pulp (such as apple juice or white grape juice)
  • Ginger ale and other sodas (not red or purple)
  • Plain Jell-O® (not red or purple)
  • Frozen juice bars (not red or purple)

CLENPIQ savings support

Download the CLENPIQ coupon to help eligible patients save

Clenpiq Coupon

The coupon can be used for commercially insured and cash-paying patients

Download the CLENPIQ coupon and your patients may be eligible to pay as little as $40 if they have
commercial insurance, or to take $40 off the cash price. Terms and conditions apply.

Healthcare providers may download up to 10 cards at a time.

*Plus applicable sales tax. Subject to eligibility and maximum benefit allowed.

References
  1. CLENPIQ® [Prescribing Information]. Parsippany, NJ: Ferring Pharmaceuticals Inc.
  2. Hookey L, et al. Efficacy and safety of a ready-to-drink bowel preparation for colonoscopy: a randomized, controlled, non-inferiority trial. Therap Adv Gastroenterol. 2019;12:1756284819851510.
  3. Lichtenstein GR, Cohen LB, Uribarri J. Review article: bowel preparation for colonoscopy the importance of adequate hydration. Aliment Pharmacol Ther. 2007;26(5):633-641.
  4. SUPREP® Bowel Prep Kit [Prescribing Information]. Braintree, MA: Braintree Laboratories, Inc.
  5. PLENVU® [Prescribing Information]. Bridgewater, NJ: Salix Pharmaceuticals.
  6. MoviPrep® [Prescribing Information]. Bridgewater, NJ: Salix Pharmaceuticals.

Indication and Important Safety Information

Indication

CLENPIQ® oral solution is indicated for cleansing of the colon as a preparation for colonoscopy in adults and pediatric patients ages 9 years and older.

Important Safety Information

  • CLENPIQ is contraindicated in the following conditions: patients with severe reduced renal impairment (creatinine clearance less than 30mL/minute), gastrointestinal obstruction or ileus, bowel perforation, toxic colitis or toxic megacolon, gastric retention, or in patients with a known hypersensitivity to any of the ingredients in CLENPIQ.
  • Patients should be advised to hydrate adequately (before, during and after use of CLENPIQ), and post-colonoscopy lab tests should be considered if a patient develops significant vomiting or signs of dehydration, including orthostatic hypotension, after taking CLENPIQ. Patients with electrolyte abnormalities should have them corrected before treatment. Use caution when prescribing CLENPIQ for patients that have conditions or are using medications that increase the risk for fluid and electrolyte disturbances.
  • Use caution in patients who have conditions, or are taking concomitant medications that increase the risk for seizures, such as those taking medications that lower the seizure threshold, patients withdrawing from alcohol or benzodiazepines or patients with known or suspected hyponatremia.
  • Use caution in patients with impaired renal function or taking medications that may affect renal function, as well as patients at increased risk of arrhythmias, including those patients with a history of prolonged QT, recent myocardial infarction, unstable angina, congestive heart failure, or cardiomyopathy.
  • Osmotic laxatives may produce colonic mucosal aphthous ulcerations and there have been reports of more serious cases of ischemic colitis requiring hospitalization. Concurrent use of additional stimulant laxatives with CLENPIQ may increase this risk.
  • Use with caution in patients with severe active ulcerative colitis.
  • Patients with impaired gag reflex are at risk for regurgitation or aspiration during administration of CLENPIQ. Observe these patients during administration of CLENPIQ.
  • The most common adverse reactions reported in a clinical trial with CLENPIQ for colon cleansing in adults were nausea, headache, hypermagnesemia, abdominal pain, and dehydration or dizziness. The most common adverse reactions reported in a clinical trial of another sodium picosulfate, magnesium oxide and anhydrous citric acid product for colon cleansing in pediatric patients aged 9 to 16 years were nausea, vomiting and abdominal pain.
  • CLENPIQ can reduce the absorption of co-administered drugs. Do not take oral medications within one hour of starting CLENPIQ. Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine and penicillamine, at least 2 hours before and not less than 6 hours after administration of CLENPIQ to avoid chelation with magnesium.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch, or call 800.FDA.1088.
Please see accompanying full Prescribing Information.

Indication and Important Safety Information

Indication

CLENPIQ® oral solution is indicated for cleansing of the colon as a preparation for colonoscopy in adults and pediatric patients ages 9 years and older.

Important Safety Information

  • CLENPIQ is contraindicated in the following conditions: patients with severe reduced renal impairment (creatinine clearance less than 30mL/minute), gastrointestinal obstruction or ileus, bowel perforation, toxic colitis or toxic megacolon, gastric retention, or in patients with a known hypersensitivity to any of the ingredients in CLENPIQ.
  • Patients should be advised to hydrate adequately (before, during and after use of CLENPIQ), and post-colonoscopy lab tests should be considered if a patient develops significant vomiting or signs of dehydration, including orthostatic hypotension, after taking CLENPIQ. Patients with electrolyte abnormalities should have them corrected before treatment. Use caution when prescribing CLENPIQ for patients that have conditions or are using medications that increase the risk for fluid and electrolyte disturbances.
  • Use caution in patients who have conditions, or are taking concomitant medications that increase the risk for seizures, such as those taking medications that lower the seizure threshold, patients withdrawing from alcohol or benzodiazepines or patients with known or suspected hyponatremia.
  • Use caution in patients with impaired renal function or taking medications that may affect renal function, as well as patients at increased risk of arrhythmias, including those patients with a history of prolonged QT, recent myocardial infarction, unstable angina, congestive heart failure, or cardiomyopathy.
  • Osmotic laxatives may produce colonic mucosal aphthous ulcerations and there have been reports of more serious cases of ischemic colitis requiring hospitalization. Concurrent use of additional stimulant laxatives with CLENPIQ may increase this risk.
  • Use with caution in patients with severe active ulcerative colitis.
  • Patients with impaired gag reflex are at risk for regurgitation or aspiration during administration of CLENPIQ. Observe these patients during administration of CLENPIQ.
  • The most common adverse reactions reported in a clinical trial with CLENPIQ for colon cleansing in adults were nausea, headache, hypermagnesemia, abdominal pain, and dehydration or dizziness. The most common adverse reactions reported in a clinical trial of another sodium picosulfate, magnesium oxide and anhydrous citric acid product for colon cleansing in pediatric patients aged 9 to 16 years were nausea, vomiting and abdominal pain.
  • CLENPIQ can reduce the absorption of co-administered drugs. Do not take oral medications within one hour of starting CLENPIQ. Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine and penicillamine, at least 2 hours before and not less than 6 hours after administration of CLENPIQ to avoid chelation with magnesium.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch, or call 800.FDA.1088.
Please see accompanying full Prescribing Information.